Alemtuzumab in the up-front setting
Matthew Kaufman, Kanti R RaiLong Island Jewish Medical Center, New Hyde Park, NY, USAAbstract: Alemtuzumab is a humanized chimeric monoclonal antibody targeting CD52. Although this agent already has an important role in the treatment of chronic lymphocytic leukemia (CLL), many of its uses are still...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-04-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Online Access: | http://www.dovepress.com/alemtuzumab-in-the-up-front-setting-a1327 |